261 related articles for article (PubMed ID: 30946148)
1. Minority and majority pretreatment HIV-1 drug resistance associated with failure of first-line nonnucleoside reverse-transcriptase inhibitor antiretroviral therapy in Kenyan women.
Milne RS; Silverman RA; Beck IA; Mckernan-Mullin J; Deng W; Sibley TR; Dross S; Kiarie JN; Sakr SR; Coombs RW; Chung MH; Frenkel LM
AIDS; 2019 May; 33(6):941-951. PubMed ID: 30946148
[TBL] [Abstract][Full Text] [Related]
2. Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya.
Chung MH; Beck IA; Dross S; Tapia K; Kiarie JN; Richardson BA; Overbaugh J; Sakr SR; John-Stewart GC; Frenkel LM
J Acquir Immune Defic Syndr; 2014 Nov; 67(3):246-53. PubMed ID: 25140907
[TBL] [Abstract][Full Text] [Related]
3. Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay.
Wagner TA; Kress CM; Beck I; Techapornroong M; Wittayapraparat P; Tansuphasawasdikul S; Jourdain G; Ngo-Giang-Huong N; Lallemant M; Frenkel LM
J Clin Microbiol; 2010 May; 48(5):1555-61. PubMed ID: 20181911
[TBL] [Abstract][Full Text] [Related]
4. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
5. Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure.
Jourdain G; Wagner TA; Ngo-Giang-Huong N; Sirirungsi W; Klinbuayaem V; Fregonese F; Nantasen I; Techapornroong M; Halue G; Nilmanat A; Wittayapraparat P; Chalermpolprapa V; Pathipvanich P; Yuthavisuthi P; Frenkel LM; Lallemant M;
Clin Infect Dis; 2010 May; 50(10):1397-404. PubMed ID: 20377404
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial.
Chung MH; McGrath CJ; Beck IA; Levine M; Milne RS; So I; Andersen N; Dross S; Coombs RW; Chohan B; Yatich N; Kiptinness C; Sakr SR; Kiarie JN; Frenkel LM
Lancet HIV; 2020 Feb; 7(2):e104-e112. PubMed ID: 31818716
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru.
Soria J; Mugruza R; Levine M; León SR; Arévalo J; Ticona E; Beck IA; Frenkel LM
AIDS Res Hum Retroviruses; 2019 Feb; 35(2):150-154. PubMed ID: 30560685
[TBL] [Abstract][Full Text] [Related]
8. Nevirapine Resistance in Previously Nevirapine-Unexposed HIV-1-Infected Kenyan Infants Initiating Early Antiretroviral Therapy.
Chohan BH; Tapia K; Benki-Nugent S; Khasimwa B; Ngayo M; Maleche-Obimbo E; Wamalwa D; Overbaugh J; John-Stewart G
AIDS Res Hum Retroviruses; 2015 Aug; 31(8):783-91. PubMed ID: 25819584
[TBL] [Abstract][Full Text] [Related]
9. Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysis.
Rath BA; von Kleist M; Castillo ME; Kolevic L; Caballero P; Soto-Castellares G; Amedee AM; Robinson JE; Katzenstein DK; Van Dyke RB; Oberhelman RA
BMC Infect Dis; 2013 Jan; 13():1. PubMed ID: 23280237
[TBL] [Abstract][Full Text] [Related]
10. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.
Metzner KJ; Scherrer AU; von Wyl V; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Hirsch HH; Vernazza PL; Cavassini M; Calmy A; Bernasconi E; Weber R; Günthard HF;
AIDS; 2014 Sep; 28(15):2231-9. PubMed ID: 25036184
[TBL] [Abstract][Full Text] [Related]
11. Resistance mutations in HIV-1 infected pregnant women and their infants receiving antiretrovirals to prevent HIV-1 vertical transmission in China.
Han J; Wang L; Jiang Y; Zhang Q; Fang L; Yao J; Wang Q
Int J STD AIDS; 2009 Apr; 20(4):249-54. PubMed ID: 19304969
[TBL] [Abstract][Full Text] [Related]
12. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.
Coovadia A; Hunt G; Abrams EJ; Sherman G; Meyers T; Barry G; Malan E; Marais B; Stehlau R; Ledwaba J; Hammer SM; Morris L; Kuhn L
Clin Infect Dis; 2009 Feb; 48(4):462-72. PubMed ID: 19133804
[TBL] [Abstract][Full Text] [Related]
13. Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART.
MacLeod IJ; Rowley CF; Thior I; Wester C; Makhema J; Essex M; Lockman S
J Clin Virol; 2010 Jul; 48(3):162-7. PubMed ID: 20427228
[TBL] [Abstract][Full Text] [Related]
14. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.
Li JZ; Paredes R; Ribaudo HJ; Svarovskaia ES; Metzner KJ; Kozal MJ; Hullsiek KH; Balduin M; Jakobsen MR; Geretti AM; Thiebaut R; Ostergaard L; Masquelier B; Johnson JA; Miller MD; Kuritzkes DR
JAMA; 2011 Apr; 305(13):1327-35. PubMed ID: 21467286
[TBL] [Abstract][Full Text] [Related]
15. Nevirapine hair and plasma concentrations and HIV-1 viral suppression among HIV infected ante-partum and post-partum women attended in a mother and child prevention program in Maputo city, Mozambique.
Cuco RM; Loquiha O; Juga A; Couto A; Meggi B; Vubil A; Sevene E; Osman N; Temermam M; Degomme O; Sidat M; Bhatt N
PLoS One; 2022; 17(2):e0261522. PubMed ID: 35143515
[TBL] [Abstract][Full Text] [Related]
16. Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.
Kakehasi FM; Tupinambás U; Cleto S; Aleixo A; Lin E; Melo VH; Aguiar RA; Pinto JA
AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1515-20. PubMed ID: 18160009
[TBL] [Abstract][Full Text] [Related]
17. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
18. Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.
Boltz VF; Bao Y; Lockman S; Halvas EK; Kearney MF; McIntyre JA; Schooley RT; Hughes MD; Coffin JM; Mellors JW;
J Infect Dis; 2014 Mar; 209(5):703-10. PubMed ID: 24443547
[TBL] [Abstract][Full Text] [Related]
19. Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission.
Lehman DA; Chung MH; Mabuka JM; John-Stewart GC; Kiarie J; Kinuthia J; Overbaugh J
J Acquir Immune Defic Syndr; 2009 Aug; 51(5):522-9. PubMed ID: 19502990
[TBL] [Abstract][Full Text] [Related]
20. A viral genome wide association study and genotypic resistance testing in patients failing first line antiretroviral therapy in the first large countrywide Ethiopian HIV cohort.
Telele NF; Kalu AW; Gebre-Selassie S; Fekade D; Marrone G; Grossmann S; Neogi U; Tegbaru B; Sönnerborg A
BMC Infect Dis; 2019 Jul; 19(1):569. PubMed ID: 31262272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
